SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

July 22, 2022

Study Completion Date

January 9, 2024

Conditions

Metastatic Non-small Cell Lung CancerMetastatic Triple-negative Breast Cancer

Interventions

BIOLOGICAL

ADV/HSV-tk

Replication-defective recombinant adenovirus vector

DRUG

Valacyclovir

Prodrug of the antiviral drug acyclovir

RADIATION

SBRT

Low-dose SBRT

DRUG

Pembrolizumab

Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody

Trial Locations (1)

Houston Methodist Cancer Center, Houston

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER

NCT03004183 - SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC | Biotech Hunter | Biotech Hunter